As shown in Table 1, the incidence of adrenal insufficiency in NSCLC receiving anti-CTLA-4 was significantly higher than that of patients treated with anti-PD-1/PD-L1 drugs. Here, CTLA4 is linked to non-small cell lung carcinoma.